-
“ALS Patient Is Living His Second Miracle: Follow-up stem-cell operation has more amazing results”
November 30, 2012
“We’ve got to turn Lou Gehrig’s disease into Lou Gehrig’s chronic illness,” Ted Harada says three months following his impactful second treatment in Neuralstem’s ALS Phase I trial. In this follow-up interview, Ted reports that there’s a spring in his step – along with increased strength, a strong grip, and ALS symptoms again “in retreat.”
-
“Can Patients Scoop Clinical Trial Results?”
An ex-scientist and professional investor and analyst shares insights on, and examples of, smart online and social media “detective work,” to gain additional intelligence when investing in biotech.
-
“Stem cell therapy helps paraplegic rats regain movement”
NSI-566/spinal cord injury animal research, following report in the scientific journal CELL, is reported by UK-based industry publication.
-
“Paralyzed Rats Walk Again After Stem Cell Transplant:
The rodent recovery spurs hope that humans could one day benefit from similar treatments.”
Susan Young, who recently reported on progress of NSI-566 cell therapy in the ongoing ALS trial, examines CELL spinal cord injury research study, noting promise of both clinical and pre-clinical trials utilizing NSI-566 neural stem cells.
-
"Neuralstem Gains on Stem Cell Therapy for Paralyzed Rats"
“…the last piece of the puzzle…” to move Neuralstem’s human spinal cord injury trial forward is projected by Neuralstem’s CEO Richard Garr in this article focused on the SCI study published in scientific journal CELL.
More Articles...
- Stem Cells Help Rats Recover Lower-Body Movement
- Game Changer for the Human Genome Sector?
- Henry County man undergoes experimental ALS stem cell surgery
- New Cells for ALS Patients: Surgeons have transplanted a second dose of neural cells into a patient’s spinal cord in a pioneering trial.
- Landmark Surgery for ALS Patient Ted Harada Set for Today
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.